195 related articles for article (PubMed ID: 35878189)
21. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
Kim JW; Park JH; Park KN; Lee SW
ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
[TBL] [Abstract][Full Text] [Related]
22. The effect of unilateral thalamic deep brain stimulation on the vocal dysfunction in a patient with spasmodic dysphonia: interrogating cerebellar and pallidal neural circuits.
Poologaindran A; Ivanishvili Z; Morrison MD; Rammage LA; Sandhu MK; Polyhronopoulos NE; Honey CR
J Neurosurg; 2018 Feb; 128(2):575-582. PubMed ID: 28304188
[TBL] [Abstract][Full Text] [Related]
23. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
24. Quality of Life After Botulinum Toxin Injection in Patients With Adductor Spasmodic Dysphonia; a Systematic Review and Meta-analysis.
Faham M; Ahmadi A; Silverman E; Harouni GG; Dabirmoghaddam P
J Voice; 2021 Mar; 35(2):271-283. PubMed ID: 31477348
[TBL] [Abstract][Full Text] [Related]
25. Botulinum toxin therapy for abductor spasmodic dysphonia.
Woodson G; Hochstetler H; Murry T
J Voice; 2006 Mar; 20(1):137-43. PubMed ID: 16126369
[TBL] [Abstract][Full Text] [Related]
26. Botulinum Toxin-A Dosing Trends for Adductor Spasmodic Dysphonia at a Single Institution Over 10 Years.
Bradley JP; Barrow EM; Hapner ER; Klein AM; Johns MM
J Voice; 2017 May; 31(3):363-365. PubMed ID: 27839987
[TBL] [Abstract][Full Text] [Related]
27. Identification of symptoms for spasmodic dysphonia and vocal tremor: a comparison of expert and nonexpert judges.
Barkmeier JM; Case JL; Ludlow CL
J Commun Disord; 2001; 34(1-2):21-37. PubMed ID: 11322567
[TBL] [Abstract][Full Text] [Related]
28. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia.
Troung DD; Rontal M; Rolnick M; Aronson AE; Mistura K
Laryngoscope; 1991 Jun; 101(6 Pt 1):630-4. PubMed ID: 2041443
[TBL] [Abstract][Full Text] [Related]
29. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.
Tsuji DH; Takahashi MT; Imamura R; Hachiya A; Sennes LU
J Voice; 2012 Sep; 26(5):666.e7-12. PubMed ID: 21940146
[TBL] [Abstract][Full Text] [Related]
30. Life Threatening Delayed Complication of Botulinum Toxin Injection for Treatment of Spasmodic Dysphonia.
Yershov D; Partridge R
Prague Med Rep; 2020; 121(2):114-117. PubMed ID: 32553095
[TBL] [Abstract][Full Text] [Related]
31. [Treatment efficacy of electronic endoscope-guided botulinum toxin injection in adductor spasmodic dysphonia patients].
Ren J; Yang H; Wang H; Zou J; Lv D; Yu L; Zheng Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Nov; 34(11):1019-1023. PubMed ID: 33254323
[No Abstract] [Full Text] [Related]
32. Botulinum toxin injection for abductor spasmodic dysphonia under cervical ultrasonography guidance.
Kunieda C; Nin F; Ohashi T; Hosokawa K; Watanabe Y; Ogawa T; Mori T; Kanazawa T
Auris Nasus Larynx; 2024 Apr; 51(2):361-364. PubMed ID: 37838568
[TBL] [Abstract][Full Text] [Related]
33. Post-treatment clinical course following botulinum toxin injection therapy for adductor spasmodic dysphonia: Analysis of data from a placebo-controlled, randomized, double-blinded clinical trial in Japan.
Hirose K; Asano K; Sakaguchi M; Nagao A; Nakahira M; Doi N; Kobayashi T; Hyodo M
Laryngoscope Investig Otolaryngol; 2021 Oct; 6(5):1088-1095. PubMed ID: 34667852
[TBL] [Abstract][Full Text] [Related]
34. Use of Botulinum Toxin in Spasmodic Dysphonia: A Review of Recent Studies.
Khan HA
Cureus; 2023 Jan; 15(1):e33486. PubMed ID: 36628391
[TBL] [Abstract][Full Text] [Related]
35. Botulinum toxin-B injection into the lacrimal gland and posterior cricoarytenoid muscle for the treatment of epiphora and abductor spasmodic dysphonia secondary to Parkinson's disease.
Sachdev A; Costello D; Madge S
Orbit; 2019 Jun; 38(3):248-251. PubMed ID: 29939826
[TBL] [Abstract][Full Text] [Related]
36. Current practices in the management of adductor spasmodic dysphonia.
Eskander A; Fung K; McBride S; Hogikyan N
J Otolaryngol Head Neck Surg; 2010 Oct; 39(5):622-30. PubMed ID: 20828529
[TBL] [Abstract][Full Text] [Related]
37. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review.
Watts C; Nye C; Whurr R
Clin Rehabil; 2006 Feb; 20(2):112-22. PubMed ID: 16541931
[TBL] [Abstract][Full Text] [Related]
38. Common practices in botulinum toxin injection for spasmodic dysphonia treatment: A national survey.
Shoffel-Havakuk H; Rosow DE; Lava CX; Hapner ER; Johns MM
Laryngoscope; 2019 Jul; 129(7):1650-1656. PubMed ID: 30582627
[TBL] [Abstract][Full Text] [Related]
39. Impact of an Upper Respiratory Tract Infection on Botulinum Toxin Efficacy in Spasmodic Dysphonia Patients.
Kirke DN; Kaye R; Blitzer A
Laryngoscope; 2020 Jul; 130(7):1746-1749. PubMed ID: 31508822
[TBL] [Abstract][Full Text] [Related]
40. Improved vocal quality and decreased vocal effort after botulinum toxin treatment for laryngeal dystonia.
Leung JS; Rosenbaum A; Holmberg J; Villarroel P; Napolitano C; Badía PI; Lagos-Villaseca A
Auris Nasus Larynx; 2024 Feb; 51(1):106-112. PubMed ID: 37365040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
